We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Apellis Pharmaceuticals Inc
18 own
17 watching
Current Price
$27.44
$-5.56
(-16.85%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
4,480.37M
52-Week High
73
52-Week Low
24.34000
Average Volume
3.96M
Dividend Yield
--
P/E Ratio
--
Market Capitalization4,480.37M52-Week High7352-Week Low24.34000Average Volume3.96MDividend Yield--P/E Ratio--What does the Apellis Pharmaceuticals Inc do?
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
Read More
How much money does Apellis Pharmaceuticals Inc make?
News & Events about Apellis Pharmaceuticals Inc.
PR Newswire
1 year ago
Thinking about trading options or stock in BILL Holdings, Apellis Pharmaceuticals, Apple, Boeing, or General Electric? Thinking about trading options or stock in BILL Holdings, Apellis Pharmaceuticals, Apple, Boeing, or General Electric? PR Newswire NEW YORK, May 5, 2023 NEW YORK, May 5, 2023...
Zolmax
1 year ago
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS Get Rating) Director Alec Machiels sold 1,250 shares of the stock in a transaction dated Monday, April 17th. The stock was sold at an average price of $81.05, for a total transaction of $101,312.50. Following the completion of the sale, the director now ...
Globe Newswire
1 year ago
Applications are under review in Canada, Australia, the United Kingdom, and SwitzerlandApproval decisions expected in the first half of 2024 WALTHAM, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, ...
Ticker Report
1 year ago
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS Get Rating) Director Alec Machiels sold 1,250 shares of the businesss stock in a transaction that occurred on Monday, April 17th. The shares were sold at an average price of $81.05, for a total value of $101,312.50. Following the completion ...
Ticker Report
1 year ago
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS Get Rating) insider Pascal Deschatelets sold 12,000 shares of Apellis Pharmaceuticals stock in a transaction on Monday, April 10th. The stock was sold at an average price of $78.21, for a total transaction of $938,520.00. Following the sale, the ...
Frequently Asked Questions
Frequently Asked Questions
What is Apellis Pharmaceuticals Inc share price today?
Can Indians buy Apellis Pharmaceuticals Inc shares?
How can I buy Apellis Pharmaceuticals Inc shares from India?
Can Fractional shares of Apellis Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Apellis Pharmaceuticals Inc stocks?
What is today’s traded volume of Apellis Pharmaceuticals Inc?
What is today’s market capitalisation of Apellis Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Apellis Pharmaceuticals Inc?
What percentage is Apellis Pharmaceuticals Inc down from its 52-Week High?
What percentage is Apellis Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$27.44
$-5.56
(-16.85%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.